All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)

Epidermolysis bullosa (EB) is a rare genetic condition that makes the skin extremely fragile, causing painful blisters and open wounds that struggle to heal. This phase 3 clinical trial is testing an experimental therapy made from donor stem cells (called ABCB5-positive mesenchymal stromal cells). Researchers want to see whether these healing cells can close stubborn wounds and lower pain and itching in adults with two severe forms of the condition: Recessive Dystrophic EB (RDEB) and Junctional EB (JEB). Participants will receive either the stem cell therapy or an inactive dummy treatment (placebo) through a drip. Neither the participants nor their doctors will know who gets which treatment at first. The study team will track wound healing, pain levels, and general well-being closely for up to 17 months to see if the treatment is safe and effective.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Rheacell GmbH & Co. KG
Enrolment target
119
Start
06 Dec 2022

What is this study about?

Living with epidermolysis bullosa (EB) means dealing with skin that tears and blisters at the slightest touch. For people with Recessive Dystrophic EB (RDEB) or Junctional EB (JEB), wounds can become chronic, lasting for months or even years. These wounds can be painful, itchy, and difficult to manage with everyday bandages alone.

This study tests a new treatment made from special stem cells taken from healthy donors. These cells, known as ABCB5-positive mesenchymal stromal cells, are thought to help calm inflammation and support tissue repair. Doctors hope that giving these cells directly into the bloodstream will help the body heal severe wounds from the inside out.

Because this is a phase 3 trial, it is one of the final stages of testing before a new medicine can be approved for general use. The study compares the stem cell treatment directly against a dummy treatment (placebo). The main goal is to see how many people have their main wounds completely close after six months, while also checking if the treatment reduces daily pain and improves quality of life.

Key takeaways

  • Tests a donor stem cell therapy for adults with RDEB and JEB.
  • Compares the cell drip against a dummy drip (placebo) to test its true effect.
  • Mainly looks at whether stubborn skin wounds completely heal within six months.
  • Also monitors changes in pain, itching, and everyday quality of life.
  • Involves hospital appointments and health monitoring over 17 months.

Who may be eligible?

This trial is designed for adults aged 18 and older who have a confirmed diagnosis of either Recessive Dystrophic Epidermolysis Bullosa (RDEB) or Junctional Epidermolysis Bullosa (JEB). Both men and women may take part.

To be eligible, you will generally need to have existing, long-standing open wounds that the doctors can measure and monitor over time. The study team will check your overall health to confirm that taking part is safe for you.

You might not be able to join if you have certain active infections, other severe medical illnesses, or allergies to the medications used during the infusions. Your clinical team will review your complete medical history before confirming whether you qualify.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you aged 18 or older?
  2. Have you been diagnosed with Recessive Dystrophic EB or Junctional EB?
  3. Do you have open skin wounds that have lasted for some time?
  4. Are you able to travel to a trial hospital for regular check-ups?
  5. Are you comfortable receiving medication through a drip in your vein?
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for up to 17 months in total. If you join, you will be placed by chance (randomly) into one of two groups: one group receives the donor stem cell drip, and the other receives a dummy drip (placebo). Before each infusion, you will be given common medicines, such as antihistamines, to help prevent any mild infusion reactions.

During the first six months, you will attend regular hospital appointments. At these visits, doctors will measure and photograph your wounds, take routine blood tests, and ask you questions about your pain, itching, and daily life. After the six-month mark, you will continue with follow-up appointments until month 17 so the team can monitor your health and see how long any wound healing lasts.

Potential risks and benefits

The possible benefit of joining is that the treatment could help your wounds heal and ease your pain and itching, although there is no guarantee that it will work for everyone. The main risks include side effects from the drip, such as mild allergic reactions, tiredness, or fever, which the medical team monitors closely. Taking part in this trial is entirely your choice. You are free to leave the study at any time without giving a reason, and doing so will never affect your regular NHS care.

Locations (12)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Austria
  • —
    Unverified
    Hungary
  • —
    Unverified
    Poland
  • —
    Unverified
    Italy
  • —
    Unverified
    Germany
  • —
    Unverified
    Denmark
  • —
    Unverified
    Netherlands
  • —
    Unverified
    France
  • —
    Unverified
    Croatia
  • —
    Unverified
    Greece
  • —
    Unverified
    Portugal
  • —
    Unverified
    Spain

Common questions

Will I definitely receive the stem cell therapy?

No. A computer puts participants into groups by chance. You will receive either the stem cell drip or an inactive dummy drip (placebo), and neither you nor your doctor will know which one you receive during the test period.

How is the treatment given?

The treatment is given as an infusion through a small plastic tube into a vein (an intravenous drip) at the study hospital.

Can I continue with my usual wound dressings?

Yes. You will continue to look after your skin with standard wound care and dressings alongside the study treatment.

Do I have to pay to take part?

No. All study medications, tests, and trial visits are provided free of charge, and help with travel costs is often available.

Can I leave the study if I change my mind?

Yes. You can withdraw from the study at any time, for any reason, and your usual healthcare team will continue to look after you as normal.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A double-blind, randomized, placebo-controlled, intervention…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.